Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...
Intact external limiting membrane in spectral domain-optical coherence tomography imaging is ... in patients with ME secondary to central retinal vein occlusion. The dilemma still holds regarding ...
Summary of evidence: results of anti-vascular endothelial growth factor treatment on central retinal vein occlusion ... in spectral domain-optical coherence tomography imaging is associated ...
1-3,10 DME occurs when damaged blood vessels leak into and cause swelling in the macula – the central area of ... and macular edema following retinal vein occlusion.19-24 Lucentis ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...
Objective To understand the efficacy of aspirin use for preventing ischaemic stroke after central retinal artery occlusion ... acute coronary syndrome, retinal vein occlusion, new-onset glaucoma, ...
One was a case of diabetic macular oedema; another was a case of branch retinal vein occlusion ... imaging on OCT. Based on the current evidence, it is clear that intravitreal steroids have the ...